Companion Diagnostic Market accounted for US$ 3,481.2 million in 2020 and is projected to register a CAGR of 19.5% during the forecast period 2020 – 2027

Companion diagnostics is an advanced technology that is used to target biomarker identification, reducing clinical trial cost, and time to market the product. Moreover, growing initiatives from regulatory bodies such as the U.S Food and Drug Administration (FDA) for providing a defined structure of companion diagnostic development is driving research activities in companion diagnostics.

The global companion diagnostics market size was valued at US$ 3,481.2 million in 2020 and is expected to exhibit a CAGR of 19.5 % over the forecast period (2020–2027).

Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/109

Rising incidences of cancer are projected to propel the growth of the global companion diagnostics market

Growing incidences of cancer cases are expected to drive the global companion diagnostics market growth. For instance, according to GLOBOCAN 2018, around 18.1 million new cancer cases and 9.6 million cancer deaths were recorded worldwide in 2018. Furthermore, according to the same source, in 2018, around 2,093,876 new lung cancer cases were recorded.

Moreover, growing government initiatives for the development of companion diagnostics and therapies used in the treatment of cancer patients is projected to augment the growth of the global companion diagnostics market. For instance, in 2015, the U.S. government announced the launch of the Precision Medicine Initiative, which has led to novel discoveries and several new treatments that are tailored for a specific characteristic such as person’s genetic makeup or genetic profile of an individual tumor that helps to transform the way of treatment.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/109

On the other hand, narrow labeling of companion diagnostics is projected to hamper the market growth

The rising number of cancer cases and the presence of well-established key vendors which are engaged in providing advanced companion diagnostics in North America are projected to foster the market growth

North America holds a dominant position in the global companion diagnostics market, owing to the strong presence of key players in the region which are focused on product introduction for offering advanced companion diagnostic. For instance, in June 2018, Agilent Technologies Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its Dako PD-L1 IHC 22C3 pharmDx assay. PD-L1 IHC 22C3 pharmDx is now the first FDA-approved IHC test for determining PD-L1 expression in cervical cancer and is the first FDA-approved companion diagnostic to identify patients with cervical cancer for treatment with KEYTRUDA. Moreover, rising cases of cancer in the region are further propelling the growth of the market. For instance, according to the National Cancer Institute (NCI), in April 2018, an estimated around 1,735,350 new cancer cases and 609,640 deaths due to cancer in the U.S. were recorded. Moreover, according to the same source, the most common cancers in 2018, were breast cancer, prostate cancer, melanoma, bladder cancer, pancreatic cancer, liver cancer, and other cancers, and the number of new cancer cases reported were around 439.2 per 100,000 men and women per year in the U.S. (based on 2011 to 2015 cases).

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/companion-diagnostics-market-to-surpass-us-1007-billion-by-2026-20

Key Players

Major players operating in the global companion diagnostics market include Abbott Laboratories, Agilent Technologies Inc., Danaher Corporation, Qiagen N.V., F. Hoffmann-La Roche AG, bioMerieux S.A., Illumina, Inc., GE Healthcare, Myriad Genetics Inc., and Siemens Healthineers.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.